April 2023

Editorial Board
Published in issue: April 2023
i

Submit your late-breaker abstract for the EASL Congress 2023 between 12–26 April!
Published in issue: April 2023
ii

Register for the EASL Liver Cancer Summit 2023, 20-22 April, in Estoril (Portugal)
Published in issue: April 2023
iii

Register for the EASL Monothematic Conference on Biliary Fibrosis, 12-13 May, in Florence (Italy)
Published in issue: April 2023
iv

EASL is supporting five major EU-funded projects on the liver. Discover them!
Published in issue: April 2023
v

Contents
Published in issue: April 2023
vii-ix

From the Editor's Desk

From the Editor’s Desk...
• Patrizia Burra,
• Frank Tacke,
• Vlad Ratziu,
• Stefan Zeuzem,
• Bruno Sangro,
• Paolo Angeli
Published in issue: April 2023
p673-676

JHEP at a Glance

JHEP at a glance (April 2023)
Published in issue: April 2023
e117-e128

Editorials

Eliminating cccDNA to cure hepatitis B virus infection
• Fabien Zoulim,
• Barbara Testoni
Published online: January 26, 2023
p677-680

Gut microbiota lends a helping hand to nurse liver regeneration
• Beng San Yeoh,
• Matam Vijay-Kumar
Published online: January 27, 2023
p681-683

Research Articles

NAFLD and Alcohol-Related Liver Diseases


A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
• Lung-Yi Mak,
• Ed Gane,
• Christian Schwabe,
• ...
• Min Yi,
• James Hamilton,
• Man-Fung Yuen
Published online: December 09, 2022
p684-692

Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease
• Arun J. Sanyal,
• Stephen A. Williams,
• Joel E. Lavine,
• ...
• Yi Jia,
• Katherine P. Yates,
• James Tonascia
Published online: December 13, 2022
p693-703

Viral Hepatitis


Targeting proteostasis of the HEV replicase to combat infection in preclinical models
• Fei Zhang,
• Ling-Dong Xu,
• Qian Zhang,
• ...
• Tingbo Liang,
• Pinglong Xu,
• Yao-Wei Huang
Published online: December 23, 2022
p704-716

Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models
• Jinpeng Su,
• Livia Brunner,
• Edanur Ates Oz,
• ...
• Nicolas Collin,
• Anna D. Kosinska,
• Ulrike Protzer
Published online: January 09, 2023
p717-730
Open Access

A critique and systematic review of the clinical utility of hepatitis B core-related antigen
• Celina Adraneda,
• Yong Chuan Tan,
• Ee Jin Yeo,
• Guan Sen Kew,
• Atefeh Khakpoor,
• Seng Gee Lim
Published online: December 27, 2022
p731-741

Discovery of a first-in-class orally available HBV cccDNA inhibitor
• Li Wang,
• Qihui Zhu,
• Jitao David Zhang,
• ...
• Lisa Sach-Peltason,
• John A.T. Young,
• Lu Gao
Published online: December 29, 2022
p742-753

DILI, Autoimmune, Cholestatic and Genetic Diseases


Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease
• Rongjie Ji,
• Jiayuan Chen,
• Yuyang Xie,
• ...
• Lirong Zhang,
• Dong Guo,
• Yupeng Chen
Published online: January 18, 2023
p754-769

Hepatic and Biliary Cancer


Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy
• Yao Liu,
• Zhenzhen Xun,
• Kun Ma,
• ...
• Jiabei Wang,
• Youqiong Ye,
• Lianxin Liu
Published online: January 25, 2023
p770-782

Liver Transplantation


A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation
• Andrea Schlegel,
• Matteo Mueller,
• Xavier Muller,
• ...
• Beat Müllhaupt,
• Pierre-Alain Clavien,
• Philipp Dutkowski
Published online: January 18, 2023
p783-793
Open Access

Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis
• Yiliam Fundora,
• Amelia J. Hessheimer,
• Luca Del Prete,
• ...
• Umberto Cillo,
• Wojciech G. Polak,
• Constantino Fondevila
Published online: January 20, 2023
p794-804

Experimental and Translational Hepatology


Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1
• Le Tao,
• Guangyue Yang,
• Tiantian Sun,
• ...
• Jianrong Xu,
• Hongzhuan Chen,
• Cheng Liu
Published online: January 17, 2023
p805-819

Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis
• Yuhan Yin,
• Anna Sichler,
• Josef Ecker,
• ...
• Bernhard Holzmann,
• Norbert Hüser,
• Klaus-Peter Janssen
Published online: January 18, 2023
p820-835

Reviews

Fungal infections and the fungal microbiome in hepatobiliary disorders
• Phillipp Hartmann,
• Bernd Schnabl
Published online: December 21, 2022
p836-851

Seminar

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
• Daniel Guldager Kring Rasmussen,
• Quentin M. Anstee,
• Richard Torstenson,
• ...
• Carla Yunis,
• Patrick Bossuyt,
• Morten Asser Karsdal
Published online: December 13, 2022
p852-865
Open Access

Special Sections

Expert Opinion


Beta-blockers in the era of precision medicine in patients with cirrhosis
• Agustín Albillos,
• Aleksander Krag
Published online: December 15, 2022
p866-872

Hepatology Snapshot


2D and 3D liver models
• Sarah H. Saxton,
• Kelly R. Stevens
Published online: August 26, 2022
p873-875

Case Report

A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis
• Maria Paola Anolli,
• Elisabetta Degasperi,
• Lena Allweiss,
• ...
• Maura Dandri,
• Fabien Zoulim,
• Pietro Lampertico
Published in issue: April 2023
p876-880

Letters to the Editor

Is NAFLD a key driver of brain dysfunction?
• Leontine Sandforth,
• Nermeen N. El-Agroudy,
• Andreas L. Birkenfeld
Published online: October 07, 2022
e129-e130

Reply to: “Is NAFLD a key driver of brain dysfunction?”
• Anna Hadjihambi,
• Luc Pellerin
Published online: December 30, 2022
e130-e131


Prediction of liver-related mortality in a community setting
• Carolin V. Schneider,
• Stefan Gross,
• Pavel Strnad
Published online: November 09, 2022
e131-e133

Reply to: “Prediction of liver-related mortality in a community setting”
• Hamish Innes,
• Indra Neil Guha
Published online: December 30, 2022
e134-e135

The concept of MAFLD gathers patients with distinct disease progression trajectories
• Pierre Deltenre,
• Eric Trépo,
• Christophe Moreno
Published online: November 16, 2022
e135-e136


NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: A meta-analysis
• Ying Wang,
• Yadong Wang,
• Guangcai Duan,
• Haiyan Yang
Published online: October 25, 2022
e136-e139

Liver transplant for alcohol-associated liver disease continues to rise 2 years into the COVID-19 pandemic especially among young adults
• Brian P. Lee,
• Jennifer L. Dodge,
• Norah A. Terrault
Published online: December 22, 2022
e139-e141

Biejia-Ruangan compound and incidence of hepatocellular carcinoma
• Lei Luo,
• Xuebing Yao,
• Wenlong Yang
Published online: November 16, 2022
e141-e142

Reply to: “Biejia-Ruangan compound and incidence of hepatocellular carcinoma”
• Dong Ji,
• Lin Tan,
• Yongping Yang
Published online: January 13, 2023
e142-e144


Global prediction of primary liver cancer incidences and mortality in 2040
• Chenxi Li,
• Wen-Qiang He
Published online: December 10, 2022
e144-e146

Corrigenda

Corrigendum to: “PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma” [J Hepatol 77 (2022) 163-176]
• Chuan-Yuan Wei,
• Meng-Xuan Zhu,
• Peng-Fei Zhang,
• ...
• Jia-Bin Cai,
• Ai-Wu Ke,
• Jia Fan
Published online: December 21, 2022
p881-882
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581]
• Heather J. Cordell,
• James J. Fryett,
• Kazuko Ueno,
• ...
• Japan-PBC-GWAS Consortium,
• US PBC Consortium,
• UK-PBC Consortium
Published online: January 11, 2023
p883